Table I.
Study characteristics: Unselected populations.
| PC group | Study ID | Other related publications | No. analyzed | Recruitment/enrollment dates | Place(s) of recruitment | |
|---|---|---|---|---|---|---|
| A, Canada | ||||||
| PC | Akbari et al, 2014 (36) | NR | 1904 | June 1998-February 2010 | Sunnybrook Health Sciences Center, Toronto, Canada; Princess Margaret Hospital, Toronto, Canada | |
| Nam et al, 2005 (57) | NR | 996 | June 1998-January 2003 | Two prostate centers at the University of Toronto (University Health Network and Sunnybrook and Women's College Health Sciences Center) | ||
| mCRPC | Struss et al, 2017a,(23) | NR | 319 | NR | NR | |
| B, Denmark | ||||||
| PC | Naslund-Koch et al, 2016 (58) | NR | 39014 | 2003-2010 | Copenhagen General Population Study | |
| C, Germany | ||||||
| PC | Maier et al, 2014 (37) | Maier 2010 (59) | 382; 92 | 1998-2007 | Ulm, Germany | |
| D, Israel | ||||||
| PC | Vazina et al, 2000 (60) | NR | 174 | 1998 | Rabin Medical Center, Sheba Medical Center or Wolfson Medical Center | |
| E, Japan | ||||||
| PC | Tanaka et al, 2009 (61) | NR | 177 | 1997-2003 | Shimane Medical University, Izumo, Japan | |
| Uchida et al, 1999 (62) | NR | 24 | NR | University of Kitasato Hospital, Sagamihara, Kanagawa, Japan | ||
| F, Spain | ||||||
| mCRPC | Romero Laorden et al, 2017a (22) NCT03075735 (PROREPAIR-B) | Cendón Flórez et al, 2017 (63); NCT3075735 (64) | 419 | NR | 38 centers across Spain | |
| G, UK | ||||||
| PC | Castro et al, 2011a (31) UKGPCS | NR | 2181 | 1990-2005 | UK Genetic Prostate Cancer Study (UKGPCS) | |
| PC | Manson-Bahr et al, 2015 (27) | NR | 63 | NR | NR | |
| PC | Leongamornlert et al, 2012 (32) UKGPCS | NR | 886 | NR | UK Genetic Prostate Cancer Study (UKGPCS) | |
| PC | Angele et al, 2004 (65) | NR | 637 | 1993-2002 | Royal Marsden NHS Trust | |
| PC | Jefferies et al, 2017a (14) | NR | 61 | NR | Welsh Cancer Bank | |
| H, USA | ||||||
| PC | Dawson et al, 2016a (66) | NR | 437 | NR | NR | |
| PC | Nicolosi et al, 2017a (19) | NR | 1158 | 2013-2016 | ||
| PC | Xia et al, 2015 (67) | NR | 20 | NR | NR; hospital-based registry | |
| PC | Abida et al, 2017 (17) | Abida et al, 2015 (68); | 451 | May 2015-unknown | Memorial Sloan Kettering Cancer Center, New York, USA | |
| Abida et al, 2016 (69); | ||||||
| Abida et al,2016 (70); | ||||||
| Cheng et al, 2017 (71) | ||||||
| PC | Feldman et al, 2014a (72) | NR | 330 | NR | Large referral laboratory | |
| PC | Myers et al, 2016a (35) | NR | 85 | NR | NR | |
| PC | Palapattu et al, 2015a (73) | NR | 9 | NR | NR | |
| PC | Browning et al, 2006 (74) | NR | 98 | 1997 | Vanderbilt Hospital, USA | |
| PC | Patel et al, 2016a (29) | Patel et al, 2017 (75) | 327 | NR | Dana Farber Cancer Institute | |
| PC | Lara et al, 2017a (34) | NR | 207; 936 | NR | NR | |
| PC | Evans et al, 2016 (28) | NR | 1090 | NR | Mayo Clinic, Cleveland Clinic, Thomas Jefferson University | |
| PC | Wu et al, 2006 (76) | NR | 84 | 1997-1998 | Mayo Clinic, USA | |
| PC | Williams et al, 1996 (47) | Gao et al, 1995 (48) | 23 | NR | University of Utah | |
| Primary PC; | Grasso et al, 2012 (26) | NR | 11; 50 | NR | University of Michigan and from the Rapid Autopsy | |
| mCRPC | Program | |||||
| Primary PC; mPC | Dall'Era et al, 2017a (77) | Glass et al, 2017 (78) | 936 | NR | NR | |
| Primary PC; mPC | Beltran et al, 2015 (79) | Beltran et al, 2015 (80) | 69; 29 | February 2013- September 2014 | Weill Cornell Medical College–New York Presbyterian Hospital | |
| Primary PC; mPC; | Beltran et al, 2013 (81) | NR | 16; 4; 25 | NR | Weill Cornell Medical College | |
| CRPC | ||||||
| mCRPC | Gambhira et al, 2016a (82) | NR | 13 | NR | NR | |
| mCRPC | Daniel et al, 2017a (83) | NR | 1911 | NR | NR | |
| mPC | Pritchard et al, 2014 (16) | NR | 60 | NR | University of Washington Prostate Cancer Biorepository | |
| mPC | Gourdin and Lilly 2016a (15) | NR | 55 | NR | NR | |
| mPC | Robbins et al, 2011 (84) | NR | 8 | NR | Rapid Autopsy Program at the University of Michigan | |
| I, Multi-national | ||||||
| PC | Fontugne et al, 2015a (38) | NR | 51 | NR | UK and USA | |
| PC | Cancer Genome Atlas 2015 (18) | NR | 333 | NR | Multiple institutions (including Australia, Brazil, Israel, UK, USA) | |
| PC | Lu et al, 2015 (24) Cancer Genome Atlas | NR | 178 | NR | NR, but presumed to be multiple institutions (including Australia, Brazil, Israel, UK, USA) (18) | |
| PC | Timms et al, 2016c (13) | NR | 84 | 1990-2011 | Transatlantic Prostate Group Cohort and commercial databank | |
| PC | Hebbring et al, 2006 (85) | NR | 1819; 1218 | NR | USA (Johns Hopkins, Tampere University Hospital, University of Michigan, Mayo Clinic); Germany (Universitätsklinikum Ulm) | |
| PC; mCRPC | Decker et al, 2016 (30) | Baca et al, 2013 (86) | 60; 150 | NR | Multiple institutions (including Australia, Brazil, Israel, UK, and USA); unclear for some institutions | |
| Primary PC; mPC | Pritchard et al, 2016 (21) Stand Up to Cancer-Prostate Cancer Foundation (SU2C-PCF) International Prostate Cancer Dream Team discovery series; MSK-IMPACT | NR | 499; 692 | 1997-2015 (multiple case series) | Royal Marsden Hospital (London, UK), University of Washington Rapid Autopsy Program (District of Columbia, USA), Weill Cornell Medical College (New York, USA), University of Michigan Rapid Autopsy Program (Michigan, USA), Memorial Sloan Kettering Cancer Center (New York, USA); 144 international centers (SU2C-PCF) | |
| mCRPC | Robinson et al, 2015 (4) | NR | 150 | NR | 8 centers, including University of Michigan Medical School, University of Washington, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Royal Marsden Institute of Cancer Research (London). Karmanos Cancer Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, and Weill-Cornell | |
| mPC | Nelson et al, 2016a (20) | NR | 569 | NR | NR but includes UK and USA | |
| J, Country not reported | ||||||
| PC | Liu et al, 2016a (87) | NR | 36 | NR | NR | |
| mCRPC | Sonpavde et al, 2017a (33) | NR | 514 | NR | NR | |
a
Abstract;
b
letter;
c
poster.
Note that some unselected populations could also present data for the selected populations. CRPC, castration resistant prostate cancer; mCRPC, metastatic castration resistant prostate cancer; mPC, metastatic prostate cancer; NR, not reported; PC, prostate cancer.